#SuvenPharma - FY 21 Annual Reports Highlights

Like & Retweet for max reach

Link : valueeducator.com/suven-pharma-f…

Read the thread below 🔽🔽
1. Company Overview
Suven Pharma is a Contract Development and Manufacturing Organization (CDMO). They support the global life sciences industry and fine chemical majors in their NCE development.
Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations.
2. Business Segments
Suven Pharma’s business comprises 3 segments - CDMO, Specialty Chemicals and Contract Technical Services
• CDMO: This is the company’s main vertical and contributes about 62% of the company’s revenues. This vertical includes the development of intermediates, small batch manufacturing for clinical trials and commercial supply of patented molecules.
The success of this business depends on a molecule moving from one phase of the clinical trials to the next and eventual commercialization. This is a high margin business as the molecules that the company manufactures are under patent.
The company currently supplies commercial quantities for 4 intermediates in the therapeutic areas of Arthritis, Diabetes, Depression and Women’s Health.
• Specialty Chemicals: The company used the capabilities they developed in the CDMO business to venture into the specialty chemicals business.
They have developed and currently supply commercial quantities of intermediates for 2 agrochemical products and commercialized another molecule by the end of FY21. This vertical contributed to about 30% of the company’s revenues in FY21.
• Contract Technical Services: This vertical combines 3 segments - revenue from technical and analytical services, royalty fee for commercial formulation and formulation development as sales. This is currently the company’s smallest vertical and it is that way by design.
They only go after very small volume, niche products with little to no competition owing to the brand market size ($2- 5 million products). So this vertical is expected to remain relatively smaller compared to the other verticals.
3. Management
Mr. Venkateswarlu Jasti (Chairman and MD) is a Post Graduate in Pharmacy from Andhra University, Visakhapatnam, and also a Post Graduate in Pharmacy from St. John University, New York, specializing in Industrial Pharmacy.
Having registered himself as a Registered Pharmacist, he successfully owned and operated a chain of 6 community pharmacies in the state of New York and New Jersey in USA from 1977 till 1989. He returned to India from the US and co-founded Suven Life Sciences Limited in 1989.
Under his leadership, Suven Life Sciences Limited developed innovative business models like CRAMS (Contract Research and Manufacturing Services) and DDDSS (Drug Discovery & Development Support Services).
He is the chief architect for the formation of Andhra Pradesh Chief Minister’s task force for Pharma during 2001 and responsible for the creation of Pharma City at Visakhapatnam by the Government of Andhra Pradesh and PHARMEXCIL (Pharmaceutical Export Promotion Council).
4. Manufacturing Facilities
The company currently has 4 manufacturing facilities
5. Capex
The company is undertaking a capex of ₹600 Cr over 3 years to upgrade its manufacturing capabilities. This is the largest ever capex done by the company since its inception.
Since their facilities are 30+ years old and customer and regulatory requirements have increased tremendously, management believes that they need to upgrade their equipment, technology and capabilities.
The company will carry out block by block upgradation and bring in more modern equipment and technologies like continuous flow chemistry.
Management believes if the investment is not done now, the company will not be able to meet customer and regulatory requirements in a few years.
The investment will be done in 3 areas:

• Relocating the R&D center due to zoning regulations, which will take 2-3 years

• Replacing the 30 year old blocks (one at a time) and installing upgraded equipment at the Suryapet facility
• Adding a new block meeting FDA and other regulatory requirements in Pashamylaram.
Management has not provided guidance on what kind of returns to expect from this capex. But they believe that in the CDMO business, you have to anticipate demand and invest ahead of time so that you can get the projects in the future.
The entire capex will be funded through internal accruals as the company has very strong cash flows and they are anticipating cash flows of ₹1000 Cr+ over the next 3 years which will be enough to service the capex along with dividend distribution.
6. Financials
The company crossed the ₹1000 Cr revenue mark for the first in FY21. Revenues grew by 20% YoY with more than 90% revenues coming from regulated markets. EBITDA grew by 14% YoY and PAT grew by 14% YoY.
Suven also has an EBITDA margin of 40%+, one of the highest in the industry.

• • •

Missing some Tweet in this thread? You can try to force a refresh

Keep Current with Value Educator

Value Educator Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!


Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @ValueEducator

May 3
#NatcoPharma - Complex generics focused manufacturer ?

Like & Retweet for Max Reach !

Link : valueeducator.com/natco-pharma-f…

Read the thread below 🔽
1. Introduction
• Natco pharma, is an India based pharmaceutical company involved in the manufacture and marketing of APIs and Finished Dosage Formulations.
• NATCO has established presence in the Domestic as well as International markets through its subsidiaries in markets like Brazil and Canada. .The US has the largest contribution out of their international business.
Read 50 tweets
May 3
#TatvaChintan Q4 Concall Highlights

Like & Retweet for Max Reach !

Link : valueeducator.com/tatva-chintan-…

Read the thread below 👇
• On going chip shortage affected SDA revenues in Q4.

• SDA are used in manufacturing of zeolites which have application in emission control of vehicles.

• Q1 and Q2 will have lower demand due semiconductor shortage.
• Got formal approval from 2 large customers for SDA segment. Supply for one of the customer will start from Q2 2023, for second customer supply is expected to start from Jan 2023.
Read 33 tweets
May 2
Long thread on #Mayur Uniquoters 🚗🚗

Like & retweet for better reach !

1. Introduction
Mayur Uniquoters is primarily engaged in the business of manufacturing and sale of PU (Polyurethane) / PVC (Poly Vinyl Chloride) synthetic leather which is widely used in different segments
such as Footwear, Furnishings, Automotive OEM, Automotive replacement market, and Automotive Exports.
Mayur Uniquoters Ltd is the largest manufacturer of artificial leather, using the 'Release Paper Transfer Coating Technology' in India.
Mayur has the largest installed capacity for manufacturing of synthetic leather in the domestic organized segment with a capacity of 4.05 million linear meters per month (LMPM) of PVC coated fabric having Italian coating lines.
Read 37 tweets
May 2
#Saregama Concall highlights 🎵🎵

Like & Retweet for better reach

1. Films & TV crossed 100 cr revenues with 15% margin

2. Currently total catalogue of songs stand at 142k vs 130k

3. sarkaru vaari paata and gangubai crossed 1 B views in 3 months
4. Launched 2 marathi movies and 1 web series in this qtr.

5. Management positive about shift from ad-based revenue to premium paid music. Globally this shift already started. In India it's expected in next 12 to 18 months. It it happens saregama will grow at much higher rate
6. Not directly impacted due to netflix. Saregama is content provider and not music/films platform.

7. QIP funds not invested in RPG group companies. Till now acquired Mango music and Issues related expenses utilized from 750 cr. Waiting for deals at good valuations.
Read 5 tweets
Apr 30
#meghmanifinechem Q4 2022 concall highlights

Like & Retweet for max reach

• Expected to grow 20-22% in volume for FY 23 and 50% in value terms. Expected revenues for FY 23 would be around 2250 cr.
• Targeting to deliver 5000 cr revenues till FY 27. (Current revenues of 1551 in FY 22).
• Entering in new Speciality Products : Epichlorohydrin and chlorinated pvc. ECH capacity will come in May June of 2022 and CPVC will be online in Q2 2023. Both of these plants needs 3 months to stabilize operations.
Read 12 tweets
Apr 29
#LaurusLabs Q4 FY22 concall highlights 💊💊

Like & Retweet for Max Reach

Check the investor resources section : valueeducator.com/investor-resou…
1. Revenues for the full year were ₹4936 Cr (3% growth YoY). Gross margin was at 55.6% and EBITDA margin was 29.1%

2. There was significant volatility in the cost of raw materials, solvents and energy. The disruption in the supply chain and logistics has increased mainly
due to the war in Russia and lockdowns in China. This is expected to continue in Q1 and normalization is expected from Q2 onwards.
Read 22 tweets

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!


0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy


3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us on Twitter!